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Abstract
Background: Therapy for acute myeloid leukemia (AML) has largely remained unchanged, and outcomes are unsatisfactory. 
We sought to analyze outcomes of AML patients enrolled in phase I studies to determine whether overall response rates 
(ORR) and mortality rates have changed over time.
Methods: A retrospective analysis was performed on 711 adult AML patients enrolling in 45 phase I clinical trials 
supported by the Cancer Therapy Evaluation Program of the National Cancer Institute from 1986 to 2009. Changes in ORR 
and mortality rates for patients enrolled in 1986 to 1990, 1991 to 1995, 1996 to 2000, 2001 to 2005, and 2006 to 2009 were 
estimated with multivariable logistic regression models. All statistical tests were two-sided.
Results: There was a statistically significant increase in AML patients enrolling in phase I clinical trials over time (1986 to 
1990: n = 61; 2006 to 2009: n = 256; P = .03). The ORR for the entire cohort was 15.4% (1986 to 1990: 8.9%, 1991 to 1995: 21.1%; 
1996 to 2000: 7.0%; 2001 to 2005: 10.0%; 2006 to 2009: 22.6%), and it statistically significantly improved over time (P < .001). 
There was a statistically significant improvement in ORRs with novel agents in combination vs single agents (ORR = 22.8% 
vs 4.7%, respectively, odds ratio = 5.95, 95% confidence interval = 3.22 to 11.9, P < .001). The 60-day mortality rate for the 
entire cohort was 22.6%, but it statistically significantly improved over time (P = .009).
Conclusions: There has been an encouraging increase in AML patients enrolling in phase I clinical studies over time. The 
improvement in ORRs appears to be partly because of the increase in combination trials and the inclusion of previously 
untreated poor-risk AML. Continued enrollment of AML patients in early phase clinical trials is vital for drug development 
and improvement in therapeutic outcomes.
Over the past four decades, the therapeutic advancements in the 
management of acute myeloid leukemia (AML) have been mini-
mal. “7+3,” defined as seven days of continuous infusion cyta-
rabine (100–200 mg/m2/day) and three days of an anthracycline 
(most commonly daunorubicin 45–90 mg/m2/day), was originally 
studied in the 1970s by Cancer and Leukemia Group B (CALGB) 
cooperative group studies and remains the standard induction 
regimen for all patients younger than 65 to 70 years who can 
withstand intensive therapy (1–4). For younger AML patients 
(≤55 years), the complete remission (CR) rate and median overall 
survival (OS) are approximately 63.9% and 18.8 months, respec-
tively, whereas outcomes are considerably worse in older AML 
patients (>55 years: CR rates <46.0% and median OS <9 months) 
(5). A  recent European retrospective analysis reviewed overall 
outcomes in greater than 48 000 AML patients (≥age 15 years) 
between 1997 and 2008. A marginal improvement was seen in 
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five-year OS, from 12.6% in 1997 to 1999 to 14.8% in 2006 to 2008, 
with no improvement in OS in those age 65 years and older (6).
Excluding all-trans retinoic acid (ATRA) and arsenic trioxide 
for acute promyelocytic leukemia (APL), no new agents have been 
approved and incorporated into standard of care for AML since 
idarubicin was approved in combination (ie, 7+3) in 1990. Induction 
regimens consisting of idarubicin vs daunorubicin have yielded 
similar outcomes (7). Gemtuzumab ozogamicin (GO), a monoclo-
nal antibody targeting CD33 antigen linked with calicheamicin, 
received accelerated approval by the United States Federal Drug 
Administration (FDA) in 2000 after GO showed efficacy as a single 
agent in relapsed and refractory AML (8,9). However, GO was with-
drawn from the United States market by Pfizer in 2010 after a con-
firmatory phase III trial revealed toxicity and efficacy concerns 
(10). A plethora of other new agents with distinct biologic activity 
have been studied in AML without successful incorporation into 
standard clinical practice. In 2015, greater than 18 000 patients are 
expected to be diagnosed with AML, with close to 11 000 deaths 
in the United States alone, and the incidence of AML is increasing 
(11,12). New therapies are urgently needed to improve treatment 
outcomes for these patients.
We retrospectively analyzed outcomes of patients with AML 
enrolled in National Cancer Institute (NCI) Cancer Therapy 
Evaluation Program (CTEP)–sponsored phase I clinical trials 
using the NCI Phase I Clinical Trials Database. Our hypothesis 
was that outcomes of AML patients enrolled in phase I studies 
are improving over time as newer and presumably more effec-
tive agents are developed.
Methods
Study Design
A retrospective analysis was performed on NCI/CTEP-sponsored 
phase I clinical studies from 1986 to 2009. The database is main-
tained by Theradex, an international contract research organi-
zation, and is kept up to date by the investigators performing 
clinical trials and the CTEP of the NCI.
Participants
Sixty-five phase I studies were identified in leukemia, and 45 of 
these studies principally enrolled AML patients between 1986 
to 2009 (Consort Diagram, Figure  1). Adults age 18  years and 
older with pathologic confirmation of AML were included in the 
analysis. Clinical and biologic features were analyzed prior to 
and after enrollment on study. All studies were conducted in 
accordance with the Declaration of Helsinki and were approved 
by the ethics committees of each of the participating centers. 
Informed consent was obtained from each participant for each 
of the studies reported.
Statistical Analysis
The primary objectives of this analysis were to estimate overall 
response rates (ORR: CR +partial remission) and all-cause early 
mortality, defined as death within 30 or 60 days of initiation of 
therapy, for the whole study and within specific subgroups of 
patients. CR with incomplete blood count recovery (CRi) was 
utilized as an ORR criterion after it was incorporated into the 
International Working Group Response Criteria for AML in 2003 
(13). Differences in the rates of mortality and ORR over time 
were explored by categorizing time into five subgroups roughly 
divided into five-year increments: 1986 to 1990, 1991 to 1995, 
1996 to 2000, 2001 to 2005, and 2006 to 2009. Changes in ORR and 
mortality rates across these year groups were estimated with 
multivariable logistic regression models adjusting for patient 
age, number of prior therapies, and white blood cell count (WBC) 
at the start of therapy. The overall effect of year group was tested 
using a Wald test of nested regression models. To determine if 
the differences in ORR and mortality by year groups was modi-
fied by patient age, number of prior therapies, or single-agent 
vs combination therapy, the corresponding interactions terms 
were included in the models and retained in the final model if 
statistically significant (P < .05). The average change in the yearly 
number of patients enrolled was estimated with a simple linear 
regression model. Differences in patient characteristics were 
described by Fisher’s exact test with a two-sided P value.
Results
Patient Characteristics
A total of 711 AML patients in 45 phase I clinical trials conducted 
between 1986 and 2009 were included in this study (Figure 1). 
Three patients were excluded from the analysis because of 
insufficient information. No AML patients were enrolled in NCI-
sponsored phase I clinical trials during the years 1989, 1994, 
1999 and 2004; thus, each subgroup consisted of four years of 
patient enrollment. As demonstrated in Figure  2, there was a 
statistically significant increase in AML patients enrolling in 
phase I clinical trials over time (1986 to 1990: n  =  61; 2006 to 
2009: n = 256; slope = 2.3 patients/year, 95% confidence interval 
[CI] = 0.45 to 4.1, P = .03). 
Table 1 displays the patient characteristics and clinical out-
comes subdivided by dates of enrollment. The median age of 
the entire patient population was 60 years (range = 18–96), with 
51.5% of patients age 60  years and older. The median age of 
patients that enrolled in phase I clinical trials increased over 
time from 47 years in 1986 to 1990 to 68 years in 2006 to 2009. 
The proportion of older patients (≥60  years) that enrolled in 
these studies increased substantially from 1986 to 1990 (18.0%) 
to 2006 to 2009 (63.7%). The median number of prior therapies 
was four (range = 0–29), with 63.3% having three or more prior 
therapies. However, the proportion of patients with three or 
more prior therapies decreased over time (1986 to 1990: 68.9%; 
2006 to 2009: 54.3%). Accordingly, the most recent cohort (2006 
to 2009) had the largest proportion of patients with 0 prior ther-
apies (24.2%), reflecting the incorporation of newly diagnosed 
poor-risk and/or older age patient populations into phase I 
trials. Median white blood cell (WBC) count was 3600/mm3 
(range = 100-342 800/mm3). Twenty-five out of 45 (55.6%) AML 
phase I studies were identified as single-agent clinical trials. 
The proportion of patients enrolling in a single-agent phase I 
study (40.6% overall) appeared to decrease over time (1986 to 
1990: 52.5%; 1991 to 1995: 67.3%; 1996 to 2000: 51.5%; 2001 to 
2005: 43.1%; 2006 to 2009: 20.3%), with a reciprocal increase in 
enrollment to combination studies.
Treatment Outcomes: Response Rates
Forty-two out of 711 (5.9%) patients did not have a response 
assessment documented and were thus excluded from the ORR 
analysis (Figure  1). The ORR for the remaining cohort of 669 
patients was 15.4% (single agent: 4.7% vs combination: 22.8%; 
odds ratio = 5.95, 95% CI = 3.22 to 11.9, P < .001). Figure 3 plots 
the ORR for (A) the whole cohort and stratified by (B) age, (C) 
number of prior therapies, and (D) type of study (ie, single 
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agent vs combination). As shown in Figure  3A, the ORRs for 
each subgroup were: 1986 to 1990: 8.9% (single agent: 0% vs 
combination: 19.2%), 1991 to 1995: 21.1% (single agent: 6.2% vs 
combination: 51.6%), 1996 to 2000: 7.0% (single agent: 1.5% vs 
combination: 12.5%), 2001 to 2005: 10.0% (single agent: 4.5% 
vs combination: 14.5%), and 2006 to 2009: 22.6% (single agent: 
10.2% vs combination: 25.8%). 
Table  2 provides estimates of odds ratios for year sub-
group and ORR. While there was a statistical difference in ORR 
between year groups, particularly an improvement in 2006 
No. of studies assessed for eligibility (n=65)
No. of studies enrolling AML and >18 years (n=45)                    
Excluded* (n=20)
No. of patients enrolled (n=714)
Excluded from analysis† (n=3)
Assessed for response                      (n=669)
Excluded for response assessment‡ (n=42)
Single-agent studies
No. of clinical trials (n=25)
No. of patients enrolled     (n=289)
Assessed for response                 (n=275)
Overall response rate       (13/275=4.7%)
Combination studies
No. of clinical trials (n=20)
No. of patients enrolled     (n=422)
Assessed for response        (n=394)
Overall response rate (90/394=22.8%)
Figure 1. Sixty-five Cancer Therapy Evaluation Program–sponsored clinical studies enrolled leukemia patients from 1986–2009. Acute myeloid leukemia (AML) patients 
age 18 years and older enrolled in 45 of these studies. *Patients younger than age 18 years and/or with a diagnosis other than AML were excluded. †Three patients were 
excluded from analysis given insufficient clinical information. ‡Forty-two patients did not have a response assessment documented and were thus excluded from this 
analysis. AML = acute myeloid leukemia.
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Figure 2. Seven hundred eleven acute myeloid leukemia (AML) patients enrolled in Cancer Therapy Evaluation Program–sponsored phase I studies from 1986–2009. 
Enrollment increased across each time period analyzed (1986–1990: n = 61; 1991–1995: n = 98; 1996–2000: n = 136; 2001–2005: n = 160; 2006–2009: n = 256).
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to 2009 compared with earlier years (P < .001), the difference 
seems to be largely driven by increased use of combination 
therapies. When comparing the overall effect of year groups 
on the probability of response (Supplementary Table  1, avail-
able online), there was a statistically significant improvement 
of ORRs over time in patients younger than age 60 years (P = .01) 
and a nonsignificant trend of improved ORRs in patients age 
60 years and older (P = .10). Notably, the ORR for those younger 
than age 60 years and age 60 years and older in 2006 to 2009 
was 26.4% and 20.4%, respectively. A test for interaction did not 
reveal any statistical differences in ORRs between age and year 
group (P = .58). Comparison of ORRs stratified by number of prior 
therapies (0 vs 1–2 vs ≥3) revealed no differences in ORR among 
those receiving zero or one to two prior therapies but statisti-
cally significant improvement over time in patients with three 
or more prior therapies (P = .001). Finally, there was also a sta-
tistically significant improvement in ORR over time in patients 
treated on combination studies (P = .03) but not on single-agent 
trials (P = .43). Test for interaction did not reveal any statistical 
differences in ORRs between type of study (ie, single agent vs 
combination) and year group (P = .51).
Treatment Outcomes: Early Mortality
All-cause early mortality was subdivided into 30-day and 
60-day mortality rates. The 30-day and 60-day mortality 
rates for the entire cohort were 11.1% (single agent: 13.8% vs 
combination: 9.2%) and 22.6% (single agent: 28.0% vs combi-
nation: 19.0%), respectively. Thirty-day mortality did not sta-
tistically significantly change over time (1986 to 1990: 11.5% 
vs 2006 to 2009: 8.6%), whereas 60-day mortality rates were 
statistically significantly higher in earlier years compared 
with 2006 to 2009 (P  =  .009). Given the apparent improve-
ment in 60-day mortality rates (when compared with 30-day 
mortality), we analyzed 60-day mortality rates as a function 
of age, number of prior therapies, and type of clinical study. 
Figure 4 depicts the 60-day mortality rates among each sub-
group for (A) the whole cohort and stratified by (B) age, (C) 
Table 1. Patient characteristics
Patient characteristics All patients 1986–1990 1991–1995 1996–2000 2001–2005 2006–2009
No. patients enrolled
No. active studies/no. new studies initiated
Age, median (range), y
711
45/-
60 (18–96)
61
11/-
47 (18–74)
98
14/10
50 (18–79)
136
11/9
57 (18–76)
160
14/11
65 (20–96)
256
11/4
68 (20–93)
<60, No. (%) 345 (48.5) 50 (81.9) 71 (72.4) 79 (58.1) 52 (32.5) 93 (36.3)
≥60, No. (%) 366 (51.5) 11 (18.0) 27 (27.6) 57 (41.9) 108 (67.5) 163 (63.7)
No. prior therapies, median (range, %) 4 (0–29) 4 (0–13) 4 (0–17) 4 (0–29) 3 (0–20) 3 (0–23)
0, No. (%) 120 (16.9) 8 (13.1) 13 (13.3) 3 (2.2) 34 (21.2) 62 (24.2)
1–2, No. (%) 141 (19.8) 11 (18.0) 13 (13.3) 18 (13.2) 44 (27.5) 55 (21.5)
≥3, No. (%) 450 (63.3) 42 (68.9) 72 (73.5) 115 (84.6) 82 (51.3) 139 (54.3)
WBC*, median (range) 3.6 (0.1–342.8) 5.8 (0.1–161.5) 3.6 (0.1–342.8) 3.3 (0.1–99.8) 3.3 (0.2–102) 3.5 (0.2–115.3)
Single agent studies, No. (%) 289 (40.6) 32 (52.5) 66 (67.3) 70 (51.5) 69 (43.1) 52 (20.3)
* White blood cell count reported as k/mm3. WBC = white blood cell.
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Figure 3. Overall response rate was analyzed with exact 95% confidence intervals across each of the time periods for (A) the entire cohort, (B) subdivided by age (<60 vs 
≥60 years), (C) subdivided by number of prior therapies (0 vs 1–2 vs ≥3), and (D) subdivided by agents studied (single agent vs combination).
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number of prior therapies, and (D) type of study (ie, single 
agent vs combination).
Table 2 provides estimates of odds ratios for year subgroup 
and 60-day mortality rates. There was a statistically significant 
improvement in 60-day mortality rates over time (P  =  .009). 
When comparing 60-day mortality rates for patient subgroups 
by year group (Supplementary Table 1, available online), there 
was a statistically significant improvement in 60-day mortality 
rates in patients younger than age 60 years (P =  .004) but not 
in patients age 60 years and older (P = .20). However, a test for 
interaction did not reveal any statistical differences in 60-day 
mortality rates between age and year group (P = .31). Similar to 
ORRs, 60-day mortality rates statistically significantly improved 
in heavily pretreated patients (ie, ≥3 prior therapies, P < .001) but 
not in patients with zero or one to two prior therapies. Finally, 
there was an improvement of 60-day mortality rates in the 
2006 to 2009 subgroup compared with earlier years in patients 
treated on combination studies (P = .08). A test for interaction 
showed no significant differences between year groups and 
type of study on the probability of 60-day mortality (P = .76).
Discussion
The persistently poor outcome of AML patients underscores 
the need for the development and implementation of novel 
agents. This retrospective analysis of CTEP-sponsored phase I 
clinical trials demonstrates an increase in the overall enroll-
ment of AML patients on phase I clinical trials over the last 
23  years. The concomitant increase in combination stud-
ies and inclusion of patients with newly diagnosed AML has 
been accompanied by an improvement in ORRs and all-cause 
early mortality rates, with a promising ORR of 22.6% from 
2006 to 2009. ORRs were shown to be improving particularly 
in younger patients (ie, <60  years) and heavily pretreated 
patients. Although causes of death were not identified in this 
analysis, early mortality improvements may be partly because 
of the advances in supportive care and antimicrobial use, 
rather than a superior safety profile of novel antileukemic 
agents.
The American Society of Clinical Oncology (ASCO) Policy 
Statement Update by Weber et  al. (14) recently commented 
on the critical importance of phase I clinical trials in cancer. 
The primary objective of phase I clinical trials is to define the 
safety and tolerability of a new drug or treatment regimen 
and to describe the dose-limiting toxicities observed during 
dose determination. The majority of phase I clinical trials also 
evaluate efficacy as a secondary endpoint. Once a tolerable 
dose and schedule are defined, clinical studies evaluating new 
oncology agents proceed only if preliminary antitumor activ-
ity is demonstrated. Thus, evaluation of response rate as a 
Table 2. Odds ratios for overall response rates and 60-day mortality by year subgroup*
Patient outcome
1984–1990 vs 2006–2009
OR (95% CI)
1991–1995 vs 2006–2009
OR (95% CI)
1996–2000 vs 2006–2009
OR (95% CI)
2001–2005 vs 2006–2009
OR (95% CI) P†
Overall response rate 0.35 (0.12 to 1) 0.77 (0.41 to 1.45) 0.25 (0.12 to 0.55) 0.35 (0.19 to 0.66) <.001
60-d mortality 1.96 (0.92 to 4.15) 2.12 (1.16 to 3.87) 2.40 (1.42 to 4.07) 1.19 (0.69 to 2.04) .009
* Odds ratios (95% confidence intervals) from multivariable logistic regression models for the association between categories of time (year on study) and overall re-
sponse rate adjusted for age (continuous), number of prior therapies, and white blood cell count. Year was grouped and compared with the reference group of studies 
in 2006–2009. CI = confidence interval; OR = odds ratio.
† P values for Wald tests from nested models for the overall effect of year groups on the probability of response or 60-day mortality.
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Figure 4. Sixty-day mortality was analyzed with exact 95% confidence intervals across each of the time periods for (A) the entire cohort, (B) subdivided by age (<60 vs 
≥60 years), (C) subdivided by number of prior therapies (0 vs 1–2 vs ≥3), and (D) subdivided by agents studied (single agent vs combination).
J. F. Zeidner et al. | 6 of 8
a
r
t
ic
le
a
r
t
ic
le
secondary endpoint is an important indicator of success in 
the design of phase I clinical studies. In fact, pembrolizumab 
and the combination of dabrafenib and trametinib were 
recently FDA approved for the treatment of melanoma based 
on the activity seen in the expansion cohorts of phase I trials 
(15,16).
Response rates are generally low in phase I clinical trials 
for all cancer subtypes. Horstmann et al. analyzed 460 phase I 
clinical trials involving 11 935 oncology patients from 1991 to 
2002 and reported a stable ORR over time of 10.6%, with an 
ORR of less than 5% in single-agent phase I clinical studies 
(17). Estey et al. reported an ORR of 6.4% in leukemia patients 
enrolling in phase I studies sponsored by the NCI/CTEP from 
1974 to 1982 (18). The ORR in AML patients seen on this study 
(15.4%) appears at least similar to these reports with a 4.7% 
ORR in single-agent studies vs 22.8% ORR in combination 
studies. The 2006 to 2009 subgroup in our evaluation enrolled 
the largest number of patients and had the highest ORR 
(22.6%) when compared with the other subgroups. Possible 
explanations for the promising ORR in the most recent cohort 
are the increased proportion of patients enrolling in combi-
nation clinical studies (79.7%) compared with single agents 
and the inclusion of newly diagnosed and/or non–heavily pre-
treated patients.
Over the last five years, there have been 23 new therapeu-
tic agents approved by the FDA for hematologic malignancies 
(chronic myeloid leukemia, n = 5; chronic lymphocytic leuke-
mia, n = 5; lymphomas, n = 5; acute lymphoblastic leukemia, 
n  =  4; multiple myeloma, n  =  3; myelofibrosis/polycythemia 
vera, n  =  1). In contrast, no new agents have been approved 
by the FDA for non-APL AML since 1990, with the exception 
of GO, which received accelerated approval in 2000 but was 
withdrawn from the market in 2010 because of safety and effi-
cacy concerns. Limitations in AML drug development include: 
1)  lack of consistent and standard treatment approaches in 
AML, which confounds the analyses of OS and disease-free 
survival endpoints, 2)  inherent molecular and clinical heter-
ogeneity of patients with AML, 3)  variability in the monitor-
ing and treatment of minimal residual disease, and 4)  initial 
evaluation of new agents restricted to patients with chemo-
resistant/refractory disease, posing heightened challenges 
for establishing markers of efficacy in an extremely poor-risk 
patient population (19,20). Designing and implementing clini-
cal trials in specific subpopulations of AML patients with con-
comitant pharmacodynamic studies to identify biomarkers of 
drug sensitivity and response may help to circumvent some of 
these shortcomings.
Given the underlying complexity in AML pathogenesis 
and the inherent heterogeneity of the AML population as a 
whole, sustained single-agent activity is unlikely. Therefore, 
the investigation of new agents in combination with mecha-
nistically complementary agents should be evaluated early in 
the drug development process. Precision-targeted approaches 
to identify patients for specific therapeutic interventions and 
immunotherapeutic strategies show tremendous promise in 
cancer. Such approaches should be evaluated early to iden-
tify effective combinatorial approaches and to accelerate drug 
approval in AML. Newly diagnosed poor-risk AML patients, 
particularly in the elderly population, should be included 
in early-phase clinical trials to increase the probability of 
identifying antileukemic activity in a non–heavily pretreated 
subgroup.
There are currently six active CTEP-sponsored clinical 
studies in AML patients (Table  3). An additional six phase 
I and three phase II trials in AML have completed accrual 
within the past two years. The active studies have a total 
planned enrollment of 412 patients. Four studies involve 
complementary combinatorial agents in newly diagnosed 
untreated patients, while two phase Ib studies examine 
single-agent ipilimumab in AML patients in CR and relapsed 
hematologic malignancies post allogeneic stem cell trans-
plantation, respectively.
This is the first comprehensive study to analyze and evalu-
ate outcomes of patients with AML treated on phase I stud-
ies, to our knowledge. This analysis was limited to phase I 
studies in order to comprehensively assess whether out-
comes are being improved early in the drug development 
process. This provides a vantage point to evaluate whether 
the appropriate patient populations and disease settings are 
being addressed early in the investigation of novel agents and 
the changes over time. Nonetheless, our evaluation of AML 
patients in early-phase clinical trials has limitations that may 
affect the generalizability of these observations. Given that 
this analysis focused only on phase I clinical studies, it would 
be important to compare these results to later-phase clini-
cal trials (ie, phase II and III) to determine whether the same 
trends and changes are occurring over time. Moreover, these 
findings relate exclusively to NCI/CTEP-sponsored phase I tri-
als; these results may be disparate when analyzing industry-
sponsored or cooperative group studies in AML. Additionally, 
a limited number of clinical variables were available for our 
analysis. We did not have access to cytogenetic or molecular 
abnormalities, types of prior therapies, performance status, 
or disease-free survival. Secondary AML (treatment related 
AML or AML preexisting from an antecedent hematologic dis-
order), a subtype of AML with an extremely poor prognosis, 
was not predefined in our database. It is likely that second-
ary AML comprised a substantial proportion of the patient 
population enrolled in these studies, particularly in the most 
recent cohorts, as newly diagnosed poor-risk AML patients 
were increasingly included in the eligibility of phase I stud-
ies. Comparing outcomes for de novo AML vs secondary AML 
would be important in the evaluation of any differences in 
ORRs and mortality rates on phase I clinical trials in these 
subsets of patients. Despite these limitations, our findings 
encompass results from 711 patients enrolled in 45 phase I 
studies over a 23-year time period. These findings, at least 
in part, reflect the general trends seen in AML accrual in the 
United States and clinical outcomes on AML phase I studies 
over time.
In conclusion, our findings reveal that there has been a 
statistically significant increase in the enrollment of AML 
patients on phase I clinical trials over the last 23 years, with 
improvement in both ORRs and 60-day mortality rates over 
time. The increasing study of combinations of novel agents, 
either with established antileukemic cytotoxic drugs or with 
other investigational agents, in early-phase AML clinical tri-
als has led to an ORR of 22.6% in 2006 to 2009. Early-phase 
clinical trials should not be the last resort for AML patients. 
Unfortunately, only 5% to 10% of adult AML patients enroll in 
clinical trials, and even fewer enroll in phase I studies (21). 
Educating patients and clinicians about the benefits of early-
phase clinical trials is necessary for successful drug develop-
ment in AML.
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Table 3. Selected active and recently completed CTEP-sponsored phase I/II studies in AML*
ClinicalTrials.gov 
identifier Phase Protocol title Primary patient population
Planned 
accrual Status
NCT01757639 I Phase I/IB study of ipilimumab in patients 
with relapsed hematologic malignan-
cies after allogeneic hematopoietic cell 
transplantation
Relapse postallogeneic stem cell trans-
plantation
40 Active
NCT01822509 I Phase I study of ipilimumab in relapsed and 
refractory high-risk Myelodysplastic Syn-
drome and AML with minimal residual 
disease
Relapsed/refractory high-risk myelod-
ysplasia and AML patients in CR with 
minimal residual disease
54 Active
NCT01861314 I Phase I study of the combination of 
bortezomib and sorafenib followed by 
decitabine in patients with AML
Untreated elderly (age ≥60 years) AML or 
untreated poor-risk AML patients and 
relapsed/refractory AML patients
30 Active
NCT02029950 I Phase I study of pomalidomide given at the 
time of lymphocyte recovery following 
induction timed sequential chemo-
therapy with cytarabine, daunorubicin, 
and etoposide (AcDVP16) in patients with 
newly diagnosed AML and high- 
risk Myelodysplastic Syndrome
Untreated poor-risk AML patients and 
high-risk myelodysplasia (≥10% blasts) 
in patients ≤65 years
63 Active
NCT01249430 I A phase I study of azacitidine in combina-
tion with MEC in relapsed and refractory 
AML
Relapsed and refractory AML 23 Recently closed to 
accrual
NCT01139970 I Phase I study of the PARP inhibitor ABT- 
888 in combination with temozolomide 
in acute leukemias
Relapsed and refractory AML or untreat-
ed poor-risk elderly (≥60 years) AML
52 Recently closed to 
accrual
NCT00588991 I Phase I study of ABT-888 in combination 
with topotecan plus carboplatin for high-
risk myeloproliferative disorders and AML 
out of myeloproliferative disorders
Untreated high-risk myeloproliferative 
neoplasms or relapsed and refractory 
myeloproliferative neoplasms/AML
104 Recently closed to 
accrual
NCT00101179 I Dose-finding trial of the histone deacety-
lase inhibitor MS-275 (NSC 706995) in 
combination with 5-azacitidine in 
patients with myelodysplastic syndromes 
(MDS), chronic myelomonocytic leukemia 
(CMMoL), and AML
Myelodysplastic syndromes and untreat-
ed poor-risk elderly (≥60 years) AML
57 Recently closed to 
accrual
NCT01132586 I Phase I study of lenalidomide and conven-
tional chemotherapy
Relapsed and refractory AML or un-
treated poor-risk AML
61 Recently closed to 
accrual
NCT01254578 I Phase I study of lenalidomide maintenance 
following allogeneic hematopoietic cell 
transplantation in patients with select 
high-risk hematological malignancies
Postallogeneic stem cell transplant 60 Recently closed to 
accrual
NCT01627041 II Randomized phase II study of epigenetic 
priming using decitabine with induction 
chemotherapy in patients with AML
Untreated poor-risk AML 180 Active
NCT01907815 II Phase II study of MEK 1/2 inhibitor 
trametinib in combination with AKT 
Inhibitor GSK2141795 in AML with RAS 
mutations
Untreated elderly (≥60 years) AML and 
relapsed/refractory AML
45 Active
NCT01253447 II Phase II study of the AKT kinase inhibitor 
MK-2206 in patients with relapsed/refrac-
tory acute myelogenous leukemia
Relapsed and refractory AML 19 Recently closed to 
accrual
NCT01361464 II Phase II trial of R115777 in previously 
untreated older adults with AML and 
baseline presence of a specific 2-gene 
expression signature ratio
Untreated elderly (>65 years) AML 21 Recently closed to 
accrual
NCT01349972 II Randomized phase II trial of timed sequen-
tial therapy with alvocidib (flavopiridol), 
Ara-C, and mitoxantrone (FLAM) vs “7 + 3” 
for adults age 70 years and younger with 
newly diagnosed AML
Untreated poor-risk AML 165 Recently closed to 
accrual
* Cooperative group studies were excluded. All Cancer Therapy Evaluation Program–sponsored studies in adult acute myeloid leukemia were included if currently 
recruiting patients (active) or recently closed to accrual within the last two years. AML = acute myeloid leukemia; CTEP = Cancer Therapy Evaluation Program; 
MEC = mitoxantrone, etoposide, cytarabine; MDS = myelodysplastic syndromes.
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